News

Gus Alva, MD, DFAPA, medical director of ATP Clinical Research, commented on the potential clinical impact of AXS-05 for agitation in Alzheimer disease, caregiver burden, and the evolving collaboration between neurology and psychiatry.

A phase 2 trial found that the oral complement factor D inhibitor vemircopan did not demonstrate efficacy over placebo in adults with acetylcholine receptor antibody–positive generalized myasthenia gravis, leading to early termination of the study.

As a 2026 SEQUINS Hall of Fame honoree, James Galvin, MD, MPH, reflected on advancing equitable dementia care, culturally relevant cognitive assessment, and improving brain health outcomes across diverse communities.

Catch up on any of the neurology headlines you may have missed from last week, compiled into 1 place by the NeurologyLive® team.

As a 2026 SEQUINS Hall of Fame honoree, George Howard, DrPH, commented on decades of stroke disparities research, the impact of the REGARDS study, and why future efforts must focus more directly on upstream risk factors.

Kinan Muhammed, MD, PhD, consultant neurologist and co-founder and Chief Medical Officer for Kneu Health, discussed how smartphone-based remote monitoring tools may help clinicians track motor and cognitive changes in Parkinson disease and dementia more continuously.

As a 2026 SEQUINS Hall of Fame honoree, Gretchen L. Birbeck, MD, MPH, reflected on her decades-long work advancing equity in global neurologic care and improving epilepsy outcomes in resource-limited settings.

William Kilgo, MD, and rising chief resident Ashley Nguyen, MD, discuss the evolving neurology residency Match process, offering guidance on competitiveness, interviews, program fit, and recruitment in the virtual era.

As a 2026 SEQUINS Hall of Fame honoree, Edwin Trevathan, MD, MPH, reflects on global pediatric neurology, community-based care delivery, and the ongoing effort to reduce neurologic health inequities worldwide.

Rebecca Wilkins, Divisional Vice President of R&D Neuromodulation at Abbott, discusses the evolving role of deep brain stimulation in Parkinson disease, including patient selection, newer DBS technologies, and integration with emerging therapies.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Stroke Awareness Month!

BIOX-101 showed early signals of reduced edema growth and improved functional outcomes in a phase 2a intracerebral hemorrhage trial, with a favorable safety profile, supporting advancement into a planned adaptive phase 2b/3 study.

Neurology News Network for the week ending May 9th, 2026. [WATCH TIME: 5 minutes]

The FDA has expanded the use of efgartigimod alfa-fcab and Hytrulo to include adults with AChR-Ab seronegative generalized myasthenia gravis, marking the first approved FcRn-targeted therapy for this patient population.

The FDA approval of ocrelizumab for pediatric RRMS expands access to a high-efficacy anti-CD20 therapy for children and adolescents with historically limited treatment options.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 8, 2026.

The FDA extended review of Eisai and Biogen’s supplemental filing for once-weekly subcutaneous lecanemab initiation in early Alzheimer disease, with a new decision date set for August 2026 amid ongoing evaluation of additional submitted data.

In this episode, Mitzi Joi Williams, MD, and Jacqueline Rosenthal, MD, review the past year in multiple sclerosis, highlighting emerging therapies, biomarkers, and evolving approaches to personalized, comprehensive care.

MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Tamara Kaplan, MD. [LISTEN TIME: 36 minutes]

Adam Vogel, PhD, Professor of Speech Neuroscience at The University of Melbourne and Chief Science Officer at Redenlab, discusses the emerging role of speech analytics as an objective, scalable biomarker in neurodegenerative disease research.

David Setboun, PharmD, MBA, CEO of PharmatrophiX, and Frank Longo, MD, PhD, Co-founder & Chairman, discuss LM11A-31’s upstream mechanism targeting p75 signaling and its potential to modify neurodegenerative disease biology.

The pediatric neurologist at Johns Hopkins Medicine provided commentary on the FDA's decision, and also discussed the evolving SMA treatment landscape in general terms. [WATCH TIME: 11 minutes]

Neurava secured a $4M NIH grant to develop and validate an AI-driven wearable platform for SUDEP risk prediction and real-time monitoring, aiming to improve clinical decision-making and early intervention in epilepsy care.

The director of the Center for Neurological Restoration at Cleveland Clinic commented on tavapadon’s D1-selective mechanism, clinical development, and potential role in treating Parkinson disease across stages. [WATCH TIME: 4 minutes]

Bill Nye, science educator and advocate, reflects on Friedreich ataxia awareness, diagnostic challenges, and the evolving role of genetics and communication in advancing care.

Srikanth Muppidi, MD, a clinical professor of adult neurology at Stanford University, discussed phase 2 findings from the KYSA-6 trial of mivocabtagene autoleucel (miv-cel; KYV-101) in MG.

In honor of Huntington Disease Awareness Month, held annually in May, the director of the Huntington's Disease Center at Northwestern Medicine discussed the design of the INVEST-HD trial.

First-time seizures were associated with more than a 5-fold increase in short-term cancer risk and persistent long-term risk in a nationwide cohort study of nearly 50,000 adults.